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Abstract
Emergence of resistance to chemotherapy and radiotherapy is a major obstacle for the successful treatment of MM
(multiple myeloma). Prednisone, vincristine and melphalan are commonly used chemotherapeutic agents for the treatment
of MM. In the current study, we examined the presence of possible cross-resistance between these drugs and gamma (c)
radiation. Prednisone, vincristine and melphalan resistant RPMI-8226 and U-266 MM cells were generated by stepwise
increasing concentrations of the drugs. The sensitive and resistant cells were exposed to 200- and 800 cGy c radiation, and
proliferation was examined by XTT {2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium
hydroxide} assay. The results showed that Prednisone- and melphalan-resistant RPMI-8226 cells were also cross-resistant
to 200 and 800 cGy c radiation application, while vincristine-resistant cells did not show resistance. On the other hand,
Prednisone-, vincristine- and melphalan-resistant U-266 cells showed cross-resistance to 200- and 800 cGy c radiation
application. These results demonstrated that MM cells resistant to anticancer agents respond to radiation in different levels.
These findings may be important in the clinical applications of radiation therapy in the treatment of vincristine resistant MM.
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1. Introduction
MM (multiple myeloma) fits in the group of plasma cell disorders
characterized by neoplastic proliferation of single clone of plasma
cell engaged in the production of a monoclonal immunoglobulin,
usually monoclonal IgG or IgA (Gahrton and Durine, 1996). Oral
administration of melphalan and Prednisone has remained a
standard form of therapy in the treatment of MM (Huang et al.,
1999). However, because of the modest success attained using
standard chemotherapy, M-2 protocol using multiple chemother-
apeutic agents (vincristine, the nitrosourea carmustine, melphalan,
cyclophosphamide and Prednisone) have been used (Case et al.,
1977). Radiotherapy used in various ways is an important adjunct
to chemotherapy in the treatment of MM (Beksac¸ et al., 2008).
Radiotherapy is necessary when:
N Local radiation therapy at higher doses (with chemotherapy in
some cases) is used in the treatment of solitary tumours in
bone or soft tissue (plasmacytomas)
N High-dose radiation to a larger part of the body may be used
to reduce tumour burden or as salvage therapy
N Local low-dose radiation therapy is sometimes used as
palliative treatment to relieve uncontrolled pain and is also
used to help prevent or treat bone fractures or spinal cord
compression
N Total body irradiation is used in conjunction with high-dose
chemotherapy prior to stem cell transplantation in order to
help kill myeloma cells in the bone marrow (www.multiple
myeloma.org/treatments/3.03.01.php)
Unfortunately, circumvention of drug resistance in MM is a
major obstacle to improve clinical outcomes for myeloma patients
(Dalton, 2002). The more critical mechanism of drug resistance in
MM are considered to reside at the cellular level. Malignant cells
may exhibit genetic instability allowing spontaneous generation of
variant forms that may result in drug resistance. Altered gene
products may result in the development of resistance at the
cellular level by causing reduced intracellular drug accumulation,
altered drug distribution within the cell, modification of the drug
target, enhanced DNA damage repair and decreased apoptosis.
Any single one or combination of these alterations may lead to
clinically significant cellular drug resistance (Gahrton and Durine,
1996).
Acquired resistance in MM involves a multidrug resistance
phenotype that imparts cross-resistance to many classes of
chemotherapeutic agents. Even the use of combination chemo-
therapy, or combination chemotherapy with radiotherapy, can result
in the emergence of clinical drug resistance (Dalton and Jove, 1999).
In this study, we examined the possible cross-resistance to
radiotherapy in Prednisone-, vincristine- and melphalan-resistant
RPMI-8226 and U-266 MM cells.
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Abbreviations: IC50 or IC20 values, the concentration of any chemical that inhibits cell proliferation 50 and 20%; MM, multiple myeloma; RPMI-8226/500 mM Pred,
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2. Materials and methods
2.1. Reagents
Prednisone and vincristine were kindly provided by Gu¨lhane
Medical School, Department of Hematology, and melphalan was
obtained from Sigma. The XTT {2,3-bis(2-methoxy-4-nitro-5-
sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide}
cell proliferation kit was obtained from Biological Industries
(Israel).
2.2. Cell lines and culture conditions
RPMI-8226 and U-266 MM cells were donated kindly by Gu¨lhane
Medical School. The cells were maintained in RPMI 1640 medium
supplemented with 2 mM L-glutamine, 10% heat-inactivated
fetal bovine serum and 100 mg/ml gentamycin sulfate in a 37uC
incubator with humidified air and 5% CO2 atmosphere. The
sublines resistant to Prednisone [RPMI-8226/500 mM Pred (RPMI-
8226 cells resistant to 500 mM Prednisolone), U-266/300 mM Pred
(U-266 cells resistant to 300 mM Prednisolone)], vincristine [RPMI-
8226/50 nM Vin (RPMI-8226 cells resistant to 50 nM vincristine),
U-266/2 nM Vin (U-266 cells resistant to 2 nM vincristine)] and
melphalan [RPMI-8226/1 mM Melp (RPMI-8226 cells resistant to
1 mMmelphalane), U-266/1 mMMelp (U-266 cells resistant to 1 mM
melphalane)] were generated by incubation of the cells by
stepwise increasing concentrations of each drug.
2.3. XTT cell proliferation assay
In order to quantify the resistance gained by RPMI-8226, and U-
266 cells after drug application, XTT assay was performed both for
sensitive and resistant sublines. The XTT assay was performed as
described previously (Baran et al., 2007). The cells (26104 cells/
well) were placed into 96-well plates and incubated for 24 h at
37uC. After 72 h treatment for the stated incubation doses of
Prednisone, vincristine and melphalan, 50 ml XTT solution was
added to each well. Plates were incubated for four more hours,
and absorbance values were read at 490 nm using a 96-well plate
reader. Finally, IC50 or IC20 values (the concentration of any
chemical that inhibits cell proliferation 50 and 20%) of the drugs
were determined.
2.4. Co-60 c radiation application
Sensitive and drug-resistant sublines of RPMI-8226 and U-266
cells were placed into 96-well plates (26104 cells/well) and
incubated in fresh medium at 37uC for 24 h. Then, plates
containing the cells were irradiated with 200 and 800 cGy with a
Theratron 780 Cobalt-60 Teletherapy Unit (AECL Medical). The
doses were selected from the literature (Cameron and Sun, 2005)
on the fact that 180 to 250 cGy/day is the commonly used acute
dose for radiotherapy of humans, and 800 cGy is the cumulative
maximum dose. Plates were incubated for 24 h, and 50 ml of XTT
reagent was applied onto the cells. Finally, the plates were read at
492 nm with 96-well plate reader.
2.5. Statistical analysis
The data is reported as the means¡S.D. Statistical analysis was
carried out using SPSS software (version 11; SPSS Inc.). The two-
tailed Student t test was used to determine statistical significance
of detected differences. P,0.05 was considered statistically
significant.
3. Results
3.1. Antiproliferative effects of chemotherapeutic
agents on drug-resistant MM cells
Sensitive RPMI-8226 and U-266 cell lines were exposed to
gradually increasing concentrations of Prednisone, vincristine and
melphalan. By this way, drug-resistant sublines of RPMI-8226
and U-266 cells were generated and named as RPMI-8226/
500 mM Pred, RPMI-8226/50 nM Vin, RPMI-8226/1 mM Melp and
U-266/300 mM Pred, U-266/2 nM Vin and U-266/1 mM Melp. In
order to make it sure if these cells are resistant to chemother-
apeutic agents, we conducted XTT cell proliferation assay.
IC50 or IC20 values were calculated from cell proliferation plots
to quantitatively compare the resistant and sensitive cells. IC50
values of Prednisone on sensitive and RPMI-8226/500 mM Pred
cells were 1308 and 2207 mM (Figure 1A), while IC20 values were
43.4 and 1624 mM for U-266 and U-266/300mM Pred, respectively
(Figure 1B). These results also show that RPMI-8226/500 mM Pred
Figure 1 Effect of Prednisone on proliferation of sensitive and Prednisone-
resistant RPMI-8226 (A) and U-266 (B) cells
IC50 and IC20 values of Prednisone for RPMI-8226 and U-266 cells were calculated
from cell proliferation plots. The XTT assays were performed using triplicate samples in
at least two independent experiments. The error bars represent the S.D.
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and U-266/300 mM Pred cells became resistant to Prednisone.
IC50 values of vincristine on sensitive and RPMI-8226/50 nM Vin
cells were 10 and 400 nM, respectively (Figure 2A). On the other
hand, IC20 values of vincristine on sensitive and U-266/2 nM Vin
cells were calculated to be 2 and 8.1 nM, respectively (Figure 2B).
These results shows a 40- and 4-fold resistance to vincristine in
RPMI-8226/50 nM and U-266/2 nM Vin cells with respect to their
sensitive controls. On the other hand, results for melphalan
resistance showed that both of the cell lines became resistant
to melphalane, since IC50 values were calculated to be 111 and
156 mM for RPMI-8226 and RPMI-8226/1 mM Melp, respectively
(Figure 3A). On the other hand, IC50 values of melphalane in U-266
and U-266/1 mM Melp were found to be 81 and 188 mM, respec-
tively (Figure 3B).
3.2. Effects of radiation on Prednisone-, vincristine-
and melphalan-resistant MM cells
Sensitive and drug-resistant RPMI-8226 and U-266 cells were
exposed to 200 and 800 cGy cobalt-60 c radiation. After 24 h
incubation, XTT assay was performed to examine the changes in
cell proliferation. Cell lines exposed to radiation were normalized
with their own non-radiated controls. The radiation effect was
compared for sensitive and drug-resistant sublines of RPMI-8226
and U-266 cell lines (Figures 4 and 5).
There were 2-fold increases in cell proliferation of RPMI-8226/
500 mM Pred (P,0.05) to both 200 and 800 cGy c radiation with
respect to its sensitive controls, whereas RPMI-8226/50 nM Vin
subline was sensitive (P.0.05) to radiation. On the other hand,
RPMI-8226/1 mM Melp-resistant cells showed 2- (P,0.05) and
2.5-fold (P,0.05) increases in cellular proliferation in 200 and 800
cGy c radiation, respectively (Figure 4).
The effect of radiation was different in U-266/1 mM Melp
subline than RPMI-8226/1 mM Melp cells. Melphalan-resistant
cells showed 1.3-fold (P,0.05) increase in proliferation in
response to 800 cGy c radiation. However, the results are similar
for vincristine- and Prednisone-resistant sublines. U-266/300 mM
Pred and U-266/2 nM Vin cells proliferated 1.7- (P,0.05) and 1.4-
fold (P,0.05) in response to 200 cGy radiation, respectively,
compared with their sensitive controls (Figure 5). On the other
hand, they both were quite sensitive to 800 cGy (P.0.05).
4. Discussion
MM remains a difficult disease to treat because of its marked
resistance to chemotherapy. With conventional treatment, not all
patients respond, and even in responding patients, complete
remissions are rare and with the extremely rare exception death is
inevitable (Bergsagel et al., 1979). Radiotherapy is also used in the
treatment of MM if plasmacytomas exists in bone or soft tissue or
as palliative treatment to relieve uncontrolled pain. MM is a very
radiosensitive tumour, as shown by the ability of radiotherapy
Figure 2 Effect of vincristine on proliferation of sensitive and vincristine-
resistant RPMI-8226 (A) and U-266 cells (B)
IC50 values of vincristine was calculated from cell proliferation plots. The XTT assays
were performed using triplicate samples in at least two independent experiments. The
error bars represent the S.D.
Figure 3 Effect of melphalan on proliferation of sensitive and vincristine-
resistant RPMI-8226 (A) and U-266 cells (B)
IC50 values of melphalan were calculated from cell proliferation plots. The XTT assays
were performed using triplicate samples in at least two independent experiments. The
error bars represent the S.D.
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alone to cure a significant proportion of patients with solitary
myeloma of bone (Gahrton and Durine, 1996). In this study, we
assessed the radiation effect on Prednisone-, vincristine- and
melphalan-resistant RPMI-8226 and U-266 MM cells.
Prednisone-, vincristine- and melphalan-resistant RPMI-8226
and U-266 cells were irradiated with 200 and 800 cGy c radiation.
The results demonstrated that vincristine-resistant RPMI-8226/50
nM Vin cells do not show any cross-resistance to radiation, while U-
266/2 nM Vin cells showed slight resistant to 200 cGy radiation,
whereas it is sensitive (P.0.05) to 800 cGy. These results are
correlated with the other studies in the literature using paclitaxel,
which has the similar effect of vincristine (Choy et al., 1993;
Liebmann et al., 1994; Milas et al., 1994; Jaakkola et al., 1996;
Gupta et al., 1997; Raitanen et al., 2002; Klappe et al., 2004). Their
results showed that paclitaxel enhanced the tumour radioresponse,
since it is a chemotherapeutic agent with potent microtubule-
stabilizing activity that arrests cells in G2-M-phase. BecauseG2 and
M are the most radiosensitive phases of the cell cycle, paclitaxel
has potential as a cell cycle-specific radiosensitizer (Klappe et al.,
2004). Vincristine is also a chemotherapeutic agent that stabilizes
microtubule activity like paclitaxel. In our study, vincristine-resistant
MM cells do not show any cross-resistance when exposed to c
radiation, and vincristine-resistant sublines are radiosensitive.
The mechanisms responsible for the cross-resistance between
radiation and melphalan have been examined in human ovarian
cancer cell lines (Milross et al., 1997). Cell lines with resistance
induced in vitro to melphalan have increased cellular levels of GSH
(glutathione) compared with drug-sensitive cell line and were
cross-resistant to radiation. In addition, depletion of GSH levels in
cell lines with acquired resistance to melphalan led to a marked
sensitization of these cells to irradiation (Milross et al., 1997). The
results from our experiment show that RPMI-8226/1 mM Melp-
resistant cells showed significant resistance to 200 and 800 cGy c
radiation. However, these results were not similar with that of U-
266/1 mMMelp subline, since it showed low levels of resistance to
800 cGy c radiation. This can be due to different GSH levels of
these two cell lines, since they were isolated from two different
patients.
In the literature, there are not many studies about the effect of
radiation and glucocorticoids (Ozols et al., 1988). However, in this
study, we found that both Prednisone-resistant RPMI-8226 and U-
266 MM cells are cross-resistant to applied 800 cGy c radiation.
As a conclusion, in this study, we evaluated the interaction
between Prednisone, vincristine, melphalan and radiation therapy in
combination against MM cells in vitro. Our results showed that
the combination of Prednisone/c radiation andmelphalan/c radiation
resulted in cross-resistance; however, vincristine/c radiation did not.
These results may suggest that clinical application of combinations
of vincristine and c radiation may increase the therapeutic efficiency
in contrast with prednisone/c radiation and melphalan/c radiation
combinations. The results of this in vitro study will be a guide to the
clinicians in the treatment of drug-resistant MM.
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